Usted buscó: fosaprepitant (Inglés - Esloveno)

aprepitant after fosaprepitant administration
aprepitant po aplikaciji fosaprepitanta

the active substance is fosaprepitant.
zdravilna učinkovina je fosaprepitant.

each vial contains 150 mg of fosaprepitant.
ena viala vsebuje 150 mg fosaprepitanta.

tabulated list of adverse reactions – fosaprepitant
seznam neželenih učinkov v preglednici - fosaprepitant

1-day regimen of fosaprepitant 150 mg in adults
1-dnevni režim zdravljenja s fosaprepitantom 150 mg pri odraslih

ivemend 150 mg powder for solution for infusion fosaprepitant
ivemend 150 mg prašek za raztopino za infundiranje fosaprepitant

the pharmacological effect of fosaprepitant is attributed to aprepitant.
farmakološki učinek fosaprepitanta je posledica delovanja aprepitanta.

each vial contains fosaprepitant dimeglumine equivalent to 150 mg fosaprepitant.
ena viala vsebuje dimegluminijev fosaprepitant, ki ustreza 150 mg fosaprepitanta.

ivemend 115 mg powder for solution for infusion fosaprepitant dimeglumine
ivemend 115 mg prašek za raztopino za infundiranje dimegluminijev fosaprepitant

please refer to the summary of product characteristics for fosaprepitant.
fosaprepitant 115 mg, liofilizirano predzdravilo aprepitanta v obliki 15- minutne infuzije, lahko prvi dan, 30 minut pred kemoterapijo za preprečevanje s kemoterapijo povzročene navzee in bruhanja (cinv; “ chemotherapy induced nausea and vomiting ”) nadomesti uporabo zdravila emend (125 mg).

fosaprepitant has not been evaluated in patients below 18 years of age.
pri bolnikih, mlajših od 18 let, fosaprepitanta niso preučevali.

for fosaprepitant and aprepitant no clinical data on exposed pregnancies are available.
za fosaprepitant in aprepitant ni na voljo kliničnih podatkov za nosečnice, ki so bile izpostavljene zdravilu.

caution is advised during concomitant administration of fosaprepitant and cyp3a4 substrates.
pri sočasni uporabi fosaprepitanta in substratov za cyp3a4 je potrebna previdnost.

fosaprepitant must not be used concurrently with pimozide, terfenadine, astemizole, or cisapride.
fosaprepitanta se ne sme uporabljati skupaj s pimozidom, terfenadinom, z astemizolom ali s cisapridom.

thus, it appears that the conversion of fosaprepitant to aprepitant can occur in multiple tissues.
pri človeku se fosaprepitant hitro pretvori v aprepitant, v 30 minutah po koncu infundiranja.

the active substance in ivemend, fosaprepitant, is a ‘prodrug’ of aprepitant.
zdravilna učinkovina v zdravilu ivemend, fosaprepitant, je „predzdravilo“ aprepitanta.

plasma concentrations of fosaprepitant are below quantifiable levels within 30 minutes of the completion of infusion.
plazemske koncentracije fosaprepitanta so v 30 minutah po koncu infuzije manjše od določljivih vrednosti.

the terminal half-life of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 11 hours.
končni razpolovni čas aprepitanta po 150 mg intravenskem odmerku fosaprepitanta je bil približno 11 ur.

in humans, fosaprepitant administered intravenously was rapidly converted to aprepitant within 30 minutes following the end of infusion.
presnova aprepitanta poteka večinoma z oksidacijo na

after reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml).
po pripravi in redčenju 1 ml raztopine vsebuje 1 mg fosaprepitanta (1 mg/ml).